Association of C-Reactive Protein, Interleukin-1 Receptor Antagonist and Adiponectin with the Metabolic Syndrome

Saltevo, Juha; Vanhala, Mauno; Kautiainen, Hannu; Kumpusalo, Esko; Laakso, Markku

doi:https://doi.org/10.1155/2007/93573

Mediators of Inflammation

On this page

Abstract References Copyright Related Articles

Research Article | Open Access

Volume 2007 | Article ID 093573 | https://doi.org/10.1155/2007/93573

Association of C-Reactive Protein, Interleukin-1 Receptor Antagonist and Adiponectin with the Metabolic Syndrome

Juha Saltevo,¹Mauno Vanhala,^2,3Hannu Kautiainen,⁴Esko Kumpusalo,^5,6and Markku Laakso⁷

Received06 Jul 2007

Accepted29 Aug 2007

Published22 Nov 2007

Abstract

This Finnish population-based study, mean age 46 years, evaluates the association of high-sensitivity C-reactive protein (hs-CRP), interleukin-1 receptor antagonist (IL-1Ra), and adiponectin with the NCEP and IDF definitions of metabolic syndrome (MetS). Adiponectin levels were higher, hs-CRP and IL-1Ra levels lower in subjects without MetS compared to subjects with MetS. If MetS was present according to both IDF and NCEP criteria, BMI, waist, triglycerides, hs-CRP, and IL-1Ra were significantly higher compared to subjects who had MetS according to either only IDF or only NCEP criteria. The hs-CRP, IL-1Ra, and adiponectin linearly correlated with the number of the components of MetS according to both definitions. Decreased levels of adiponectin and increased levels of hs-CRP and IL-1Ra are tightly associated with the components of MetS. Individuals who had MetS according to both criteria had the most adverse changes in cardiovascular risk factors.

References

World Health Orgnization, “Definition, diagnosis and classification of diabetes mellitus and its complications,” Tech. Rep. 99.2, World Health Orgnization, Geneva, Switzerland, 1999.
View at: Google Scholar
“Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001.
View at: Publisher Site | Google Scholar
S. M. Grundy, B. Hansen, S. C. Smith Jr., J. I. Cleeman, and R. A. Kahn, “Clinical management of metabolic syndrome: report of the American heart association/national heart, lung, and blood institute/American diabetes association conference on scientific issues related to management,” Circulation, vol. 109, no. 4, pp. 551–556, 2004.
View at: Publisher Site | Google Scholar
International Diabetes Federation, “The IDF consensus worldwide definition of the metabolic syndrome,” October 2005, http://www.idf.org/webdata/docs/metac_syndrome_def.pdf.
View at: Google Scholar
K. G. M. M. Alberti, P. Zimmet, and J. Shaw, “The metabolic syndrome: a new worldwide definition,” The Lancet, vol. 366, no. 9491, pp. 1059–1062, 2005.
View at: Publisher Site | Google Scholar
C. Weyer, T. Funahashi, S. Tanaka et al., “Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia,” Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 5, pp. 1930–1935, 2001.
View at: Publisher Site | Google Scholar
Y. Matsuzawa, “Adipocytokines and metabolic syndrome,” Seminars in Vascular Medicine, vol. 5, no. 1, pp. 34–39, 2005.
View at: Publisher Site | Google Scholar
T. Kadowaki and T. Yamauchi, “Adiponectin and adiponectin receptors,” Endocrine Reviews, vol. 26, no. 3, pp. 439–451, 2005.
View at: Publisher Site | Google Scholar
J. C. Pickup and M. A. Crook, “Is type II diabetes mellitus a disease of the innate immune system?” Diabetologia, vol. 41, no. 10, pp. 1241–1248, 1998.
View at: Publisher Site | Google Scholar
A. J. G. Hanley, A. Festa, R. B. D'Agostino Jr. et al., “Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity,” Diabetes, vol. 53, no. 7, pp. 1773–1781, 2004.
View at: Publisher Site | Google Scholar
P. M. Ridker, “Clinical application of C-reactive protein for cardiovascular disease detection and prevention,” Circulation, vol. 107, no. 3, pp. 363–369, 2003.
View at: Publisher Site | Google Scholar
D. E. Laaksonen, L. Niskanen, K. Nyyssönen, K. Punnonen, T.-P. Tuomainen, and J. T. Salonen, “C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study,” European Heart Journal, vol. 26, no. 17, pp. 1783–1789, 2005.
View at: Publisher Site | Google Scholar
M. Soinio, J. Marniemi, M. Laakso, S. Lehto, and T. Rönnemaa, “High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes,” Diabetes Care, vol. 29, no. 2, pp. 329–333, 2006.
View at: Publisher Site | Google Scholar
D. E. Laaksonen, L. Niskanen, K. Nyyssönen et al., “C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men,” Diabetologia, vol. 47, no. 8, pp. 1403–1410, 2004.
View at: Publisher Site | Google Scholar
A. D. Pradhan, J. E. Manson, N. Rifai, J. E. Buring, and P. M. Ridker, “C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus,” Journal of the American Medical Association, vol. 286, no. 3, pp. 327–334, 2001.
View at: Publisher Site | Google Scholar
P. M. Ridker, N. Rifai, L. Rose, J. E. Buring, and N. R. Cook, “Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events,” The New England Journal of Medicine, vol. 347, no. 20, pp. 1557–1565, 2002.
View at: Publisher Site | Google Scholar
N. Sattar, A. Gaw, O. Scherbakova et al., “Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study,” Circulation, vol. 108, no. 4, pp. 414–419, 2003.
View at: Publisher Site | Google Scholar
M. Hassinen, T. A. Lakka, P. Komulainen, H. Gylling, A. Nissinen, and R. Rauramaa, “C-reactive protein and metabolic syndrome in elderly women: a 12-year follow-up study,” Diabetes Care, vol. 29, no. 4, pp. 931–932, 2006.
View at: Publisher Site | Google Scholar
S. M. Haffner, “The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease,” The American Journal of Cardiology, vol. 97, no. 2, supplement 1, pp. 3–11, 2006.
View at: Publisher Site | Google Scholar
P. M. Ridker, “C-reactive protein, inflammation, and cardiovascular disease: clinical update,” Texas Heart Institute Journal, vol. 32, no. 3, pp. 384–386, 2005.
View at: Google Scholar
C. Gabay and I. Kushner, “Acute-phase proteins and other systemic responses to inflammation,” The New England Journal of Medicine, vol. 340, no. 6, pp. 448–454, 1999.
View at: Publisher Site | Google Scholar
U. Salmenniemi, E. Ruotsalainen, and J. Pihlajamäki, “Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome,” Circulation, vol. 110, no. 25, pp. 3842–3848, 2004.
View at: Publisher Site | Google Scholar
G. Patti, A. D'Ambrosio, A. Dobrina et al., “Interleukin-1 receptor antagonist: a sensitive marker of instability in patients with coronary artery disease,” Journal of Thrombosis and Thrombolysis, vol. 14, no. 2, pp. 139–143, 2002.
View at: Publisher Site | Google Scholar
A. Katz, S. S. Nambi, K. Mather et al., “Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans,” Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 7, pp. 2402–2410, 2000.
View at: Publisher Site | Google Scholar
P. H. Westfall, R. D. Tobias, D. Rom, R. D. Wolfinger, and Y. Hochberg, Multiple Comparisons and Multiple Tests Using the SAS System, SAS Institute, Cary, NC, USA, 1999.
J. R. Landis and G. G. Koch, “The measurement of observer agreement for categorical data,” Biometrics, vol. 33, no. 1, pp. 159–174, 1977.
View at: Publisher Site | Google Scholar
M.-S. Lin, S.-R. Shih, H.-Y. Li et al., “Serum C-reactive protein levels correlates better to metabolic syndrome defined by international diabetes federation than by NCEP ATP III in men,” Diabetes Research and Clinical Practice, vol. 77, no. 2, pp. 286–292, 2007.
View at: Publisher Site | Google Scholar
C. Lorenzo, K. Williams, K. J. Hunt, and S. M. Haffner, “The national cholesterol education program-adult treatment panel III, international diabetes federation, and world health organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes,” Diabetes Care, vol. 30, no. 1, pp. 8–13, 2007.
View at: Publisher Site | Google Scholar
Y. Okamoto, S. Kihara, T. Funahashi, Y. Matsuzawa, and P. Libby, “Adiponectin: a key adipocytokine in metabolic syndrome,” Clinical Science, vol. 110, no. 3, pp. 267–278, 2006.
View at: Google Scholar
S. E. Kahn, B. Zinman, S. M. Haffner et al., “Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes,” Diabetes, vol. 55, no. 8, pp. 2357–2364, 2006.
View at: Publisher Site | Google Scholar
J.-P. Després, “Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk,” European Heart Journal Supplements, vol. 8, supplement B, pp. B4–B12, 2006.
View at: Publisher Site | Google Scholar
Y. Wang, E. B. Rimm, M. J. Stampfer, W. C. Willett, and F. B. Hu, “Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men,” American Journal of Clinical Nutrition, vol. 81, no. 3, pp. 555–563, 2005.
View at: Google Scholar
M. A. Banerji, N. Faridi, R. Atluri, R. L. Chaiken, and H. E. Lebovitz, “Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men,” Journal of Clinical Endocrinology & Metabolism, vol. 84, no. 1, pp. 137–144, 1999.
View at: Publisher Site | Google Scholar
A. Festa, R. D'Agostino Jr., G. Howard, L. Mykkänen, R. P. Tracy, and S. M. Haffner, “Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS),” Circulation, vol. 102, no. 1, pp. 42–47, 2000.
View at: Google Scholar
S. Ishikawa, K. Kayaba, T. Gotoh, Y. Nakamura, and E. Kajii, “Metabolic syndrome and C-reactive protein in the general population: JMS cohort study,” Circulation Journal, vol. 71, no. 1, pp. 26–31, 2007.
View at: Publisher Site | Google Scholar
M. Santaniemi, Y. A. Kesäniemi, and O. Ukkola, “Low plasma adiponectin concentration is an indicator of the metabolic syndrome,” European Journal of Endocrinology, vol. 155, no. 5, pp. 745–750, 2006.
View at: Publisher Site | Google Scholar
K. Matsushita, K. Tamakoshi, H. Yatsuya et al., “Further inflammatory information on metabolic syndrome by adiponectin evaluation,” preprint, International Journal of Cardiology, 2007.
View at: Google Scholar
F. M. Adam, M. J. Nara, and J. M. Adam, “Fasting insulin, adiponectin, hs-CRP levels and the components of metabolic syndrome,” Acta Medica Indonesiana, vol. 38, no. 4, pp. 179–184, 2006.
View at: Google Scholar
G. Q. Shaibi, M. L. Cruz, M. J. Weigensberg et al., “Adiponectin independently predicts metabolic syndrome in overweight Latino youth,” Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 5, pp. 1809–1813, 2007.
View at: Publisher Site | Google Scholar
C. Herder, M. Peltonen, W. Koenig et al., “Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes,” Diabetes, vol. 55, no. 8, pp. 2340–2346, 2006.
View at: Publisher Site | Google Scholar
E. Ruotsalainen, U. Salmenniemi, I. Vauhkonen et al., “Changes in inflammatory cytokines are related to impaired glucose tolerance in offspring of type 2 diabetic subjects,” Diabetes Care, vol. 29, no. 12, pp. 2714–2720, 2006.
View at: Publisher Site | Google Scholar
W. P. Arend and C. Gabay, “Physiologic role of interleukin-1 receptor antagonist,” Arthritis Research, vol. 2, no. 4, pp. 245–248, 2000.
View at: Publisher Site | Google Scholar
P. Ilanne-Parikka, J. G. Eriksson, J. Lindström et al., “Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the Diabetes Prevention Study cohort,” Diabetes Care, vol. 27, no. 9, pp. 2135–2140, 2004.
View at: Publisher Site | Google Scholar
C. Lara-Castro, N. Luo, P. Wallace, R. L. Klein, and W. T. Garvey, “Adiponectin multimeric complexes and the metabolic syndrome trait cluster,” Diabetes, vol. 55, no. 1, pp. 249–259, 2006.
View at: Publisher Site | Google Scholar
K. Hara, M. Horikoshi, T. Yamauchi et al., “Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome,” Diabetes Care, vol. 29, no. 6, pp. 1357–1362, 2006.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2007 Juha Saltevo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

316

Downloads

938

Citations